Market capitalization | $20.26b |
Enterprise Value | $37.13b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 17.90 |
EV/Sales (TTM) EV/Sales | 2.28 |
P/S ratio (TTM) P/S ratio | 1.24 |
P/B ratio (TTM) P/B ratio | 3.19 |
Revenue growth (TTM) Revenue growth | 8.38% |
Revenue (TTM) Revenue | $16.30b |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
12 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:
12 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:
Dec '23 | |
Current assets | 12,485 12,485 |
Fixed assets | 30,994 30,994 |
Total Assets | 43,479 43,479 |
Dec '23 | |
Equity | 8,126 8,126 |
Debt capital | 35,353 35,353 |
Total Capital | 43,479 43,479 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
Head office | Israel |
CEO | Richard Francis |
Employees | 37,226 |
Founded | 1901 |
Website | www.tevapharm.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.